卡妥索单抗治疗晚期胃癌伴腹膜转移临床研究成果入选2022ASCO年会

2022-05-30 网络网络

凌腾医药是一家专注于T细胞衔接抗体开发的临床阶段生物制药公司。该公司今日宣布，美国临床肿瘤学会（American Society of Clinical Oncology, ASCO）已接收卡妥索单抗

凌腾医药是一家专注于T细胞衔接抗体开发的临床阶段生物制药公司。该公司今日宣布，美国临床肿瘤学会（American Society of Clinical Oncology, ASCO）已接收卡妥索单抗治疗晚期胃癌伴腹膜转移的Ⅲ期临床试验第一阶段研究成果作为摘要发布。

摘要编号：e16102
摘要标题：Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.

此次公布了卡妥索单抗治疗晚期胃癌伴腹膜转移国际多中心Ⅲ期临床试验第一阶段（Stage 1）cohort A的临床数据（clinicaltrials.gov: NCT04222114）。全球每年胃癌新发病例超过100万例^【¹^】，50%以上的晚期胃癌患者在根治性切除术后出现腹膜转移，且部分合并有恶性腹水，严重影响生活质量^【²^】。由于目前缺乏对晚期胃癌伴腹膜转移的针对性疗法，这类患者在三线全身治疗失败后的预期生存期仅为2.3-2.4个月。cohort A入组的9名患者（1/3的患者已接受三线治疗）接受卡妥索单抗治疗后，中位总生存期（median overall survival）为3.4个月，伴有较明显的腹水消退。卡妥索单抗已初步展现在该适应症上的治疗潜力。

Reference

1. World Health Organization (WHO). Globocan 2020. Global Cancer Observatory. Accessed January 7, 2021. https://gco.iarc.fr/
2. 季加孚,沈琳,徐惠绵,徐瑞华,朱正纲,程向东,刘云鹏,李子禹,陕飞,孙宇,唐磊,周军,张小田.胃癌腹膜转移防治中国专家共识[J].中华胃肠外科杂志,2017,20(05):481-490.

关于卡妥索单抗

卡妥索单抗于2009年获得了欧洲药品管理局批准用于治疗EpCAM阳性恶性肿瘤引起的恶性腹水，是全球第一个上市的T细胞衔接双特异性抗体药物。卡妥索单抗结合肿瘤相关性抗原EpCAM和T细胞的CD3受体，同时通过与FcɣR招募免疫附属细胞，协同T细胞杀伤肿瘤细胞并产生潜在的肿瘤疫苗作用。目前，卡妥索单抗胃癌适应症正开展国际多中心Ⅲ期临床试验（NCT04222114），膀胱癌适应症正开展Ⅰ/Ⅱ期临床试验（NCT04799847）。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (6)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
2023-04-10 fanweitanzhen

#临床研究成果#

41 0
[GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
2022-09-25 xiongliangxl

#研究成果#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
2022-08-14 quxin068

#ASC#

23 0
[GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
2022-06-01 drj2003

#晚期胃癌#

54 0
[GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
2022-06-01 新生儿张玉军

#腹膜转移#

33 0
[GetPortalCommentsPageByObjectIdResponse(id=1797529, encodeId=37071e975292d, content=<a href='/topic/show?id=fdb722932e7' target=_blank style='color:#2F92EE;'>#临床研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22932, encryptionId=fdb722932e7, topicName=临床研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80ca273, createdName=fanweitanzhen, createdTime=Mon Apr 10 19:34:56 CST 2023, time=2023-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1898555, encodeId=1430189855526, content=<a href='/topic/show?id=0bdfe3394a4' target=_blank style='color:#2F92EE;'>#研究成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73394, encryptionId=0bdfe3394a4, topicName=研究成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=84fb152, createdName=xiongliangxl, createdTime=Sun Sep 25 00:34:56 CST 2022, time=2022-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939364, encodeId=637f1939364bc, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Aug 14 01:34:56 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1276649, encodeId=45c112e6649b3, content=<a href='/topic/show?id=59ed598e816' target=_blank style='color:#2F92EE;'>#晚期胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59878, encryptionId=59ed598e816, topicName=晚期胃癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579005, encodeId=628f15e9005d1, content=<a href='/topic/show?id=0ff4856621f' target=_blank style='color:#2F92EE;'>#腹膜转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85662, encryptionId=0ff4856621f, topicName=腹膜转移)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e6d16475304, createdName=新生儿张玉军, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623877, encodeId=8f4516238e733, content=<a href='/topic/show?id=16ba8564526' target=_blank style='color:#2F92EE;'>#腹膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85645, encryptionId=16ba8564526, topicName=腹膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=93e220615097, createdName=xuyong530, createdTime=Wed Jun 01 04:34:56 CST 2022, time=2022-06-01, status=1, ipAttribution=)]
2022-06-01 xuyong530

#腹膜#

32 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

报道

卡妥索单抗治疗晚期胃癌伴腹膜转移临床研究成果入选2022ASCO年会

相关资讯

拓展阅读

科室

工具

服务